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Abstract 
Background: Strategies designed to advance towards malaria elimination rely on the detection and treatment of 
infections, rather than fever, and the interruption of malaria transmission between mosquitoes and humans. Mass 
drug administration with anti-malarials directed at eliminating parasites in blood, either to entire populations or 
targeting only those with malaria infections, are considered useful strategies to progress towards malaria elimination, 
but may be insufficient if applied on their own. These strategies assume a closer contact with populations, so incorpo-
rating a vector control intervention tool to those approaches could significantly enhance their efficacy. Ivermectin, an 
endectocide drug efficacious against a range of Anopheles species, could be added to other drug-based interventions. 
Interestingly, ivermectin could also be useful to target outdoor feeding and resting vectors, something not possible 
with current vector control tools, such as impregnated bed nets or indoor residual spraying (IRS).
Results: Anopheles aquasalis susceptibility to ivermectin was assessed. In vivo assessments were performed in 
six volunteers, being three men and three women. The effect of ivermectin on reproductive fitness and mosquito 
survivorship using membrane feeding assay (MFA) and direct feeding assay (DFA) was assessed and compared. The 
ivermectin lethal concentration (LC) values were LC50 = 47.03 ng/ml [44.68–49.40], LC25 = 31.92 ng/ml [28.60–34.57] 
and LC5 = 18.28 ng/ml [14.51–21.45]. Ivermectin significantly reduced the survivorship of An. aquasalis blood-fed 4 
h post-ingestion (X2 [N = 880] = 328.16, p < 0.001), 2 days post-ingestion (DPI 2) (X2 [N = 983] = 156.75, p < 0.001), 
DPI 7 (X2 [N = 935] = 31.17, p < 0.001) and DPI 14 (X2 [N = 898] = 38.63, p < 0.001) compared to the blood fed 
on the untreated control. The average number of oviposited eggs per female was significantly lower in LC5 group 
(22.44 [SD = 3.38]) than in control (34.70 [SD = 12.09]) (X2 [N = 199] = 10.52, p < 0.001) as well as the egg hatch 
rate (LC5 = 74.76 [SD = 5.48]) (Control = 81.91 [SD = 5.92]) (X2 [N = 124] = 64.24, p < 0.001). However, no differ-
ences were observed on the number of pupae that developed from larvae (Control = 34.19 [SD = 10.42) and group 
(LC5 = 33.33 [SD = 11.97]) (X2 [N = 124] = 0.96, p > 0.05).
Conclusions: Ivermectin drug reduces mosquito survivorship when blood fed on volunteer blood from 4 h to 
14 days post-ingestion controlling for volunteers’ gender. Ivermectin at mosquito sub-lethal concentrations (LC5) 
reduces fecundity and egg hatch rate but not the number of pupae that developed from larvae. DFA had significantly 
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Background
Malaria remains an important public health problem 
worldwide affecting mainly underdeveloped and devel-
oping countries in Africa, Asia and Latin America. The 
World Health Organization (WHO) estimated that 214 
million cases of malaria occurred worldwide in 2015 
[1]. Malaria elimination and eradication are present 
themes on WHO’s agenda for infectious diseases [2, 3]. 
Research institutes and policy makers have made great 
efforts worldwide in order to achieve significant reduc-
tion in malaria incidences, with the ambitious long-term 
aim of global eradication [4–7]. Approaches designed to 
progress towards malaria elimination must rely on the 
detection and treatment of infections, rather than fever, 
and comprise the concomitant use of different tools con-
cerning health surveillance improvement through tech-
nologies, applying transmission blocking by development 
of vaccines, high sensibility new generation rapid tests, 
insecticides and drugs that can, among other features, 
circumvent the resistance issue [8].
Strategies focused on mass screening and treatment 
(MSAT) and variations of it, such as focused screening 
and treatment (FSAT) and reactive case detection (RCD), 
sometimes are described as success cases, but these strat-
egies depend on several factors that can drive for failure, 
such as logistics, public health policies, population cov-
erage, and even diagnostic tool sensitivity [9]. Likewise, 
mass drug administration (MDA) using artemisinin-
based combination therapy (ACT) has been shown to be 
an effective strategy, as well as MSAT, for high-incidence 
scenarios. However, issues like community acceptance 
and drug resistance increasing are still relevant con-
cerns [9]. These are potential control measures that can 
be improved by integration with effective vector control 
interventions. Extensive use of long lasting impregnated 
nets and indoor residual spray has led to a change in the 
vector comportment from indoor to outdoor feeding and 
resting behaviour [10, 11]. This shift brings a new chal-
lenge to target outdoor malaria transmission in a sustain-
able way in order to achieve elimination [12].
Ivermectin has proven to be effective against a range of 
Anopheles species [13–16]. Ivermectin can impact four 
of five vectorial capacity variables, including daily prob-
ability of adult mosquito survivorship, daily probability a 
mosquito feeds on a human, vector competence, and vec-
tor density in relation to the host [17–20]. Treating hosts 
with a systemic insecticide, such as ivermectin, could 
circumvent the issue of outdoor transmission, as it would 
target the vector regardless of feeding habit location and 
time [17]. In addition of having an excellent safety profile 
in humans, ivermectin has proven to be effective against 
a range of other neglected diseases, such as filariasis and 
helminthiasis [21]. Furthermore, the drug presents fea-
tures in agreement with some of the malaria eradication 
research agenda (malERA) initiative recommendations, 
such as reducing adult mosquito survival rates, shifting 
age structure, reducing the proportion of older females, 
and targeting outdoor feeding and resting [6]. Moreover, 
if livestock are treated with ivermectin for malaria con-
trol, then this is coherent with the One Health concept 
since it acts against livestock parasites, improving both 
economic output and nutrient availability [22].
Ivermectin MDA, even when a single round is applied, 
reduces the survivorship of mosquitoes, shifts the mos-
quito population age structure, and decreases sporozoite 
rate [23]. Modelling suggests that adding ivermectin as an 
adjunct during ACT MDA could reduce malaria trans-
mission and significantly reduce the number of MDAs 
and time to elimination [24]. Ivermectin has been used 
in MDA in Latin America for onchocerciasis control [25] 
and this infection has been eliminated in four of the six 
endemic countries. This illustrates that ivermectin MDA 
can be effectively implemented in Latin America for dis-
ease elimination. Indigenous populations are currently 
under ivermectin MDA intervention for onchocerciasis 
control in the Brazil-Venezuela border [26]. Variations 
in the mosquitocidal effect between anopheline species 
[27] and blood meals [28] make essential local studies 
regarding these features that directly affect the timing of 
ivermectin administration, a crucial parameter to form a 
useful addition to anti-malarial drugs [29].
Anopheles aquasalis seems to play an important role in 
malaria transmission in coastal regions of Latin America. 
Infection rates due to Plasmodium vivax were previously 
reported ranging from 0.5 to 1.7 %, both in outdoor and 
indoor resting mosquitoes in Venezuela [30], and in Bra-
zil the infection rate was estimated 1.18  % [31]. Since 
mosquito colonies have been established, the species has 
been used as a model for assessing vector-parasite inter-
actions [32]. Anopheles aquasalis has been described as 
presenting variable feeding behaviour, both anthropo-
philic and zoophilic [30, 31]. It was also designated as a 
widely distributed and abundant species [32, 33], being 
reported both at Atlantic and Pacific coasts, from Central 
higher effects on mosquito survival compared to MFA. The findings are presented and discussed through the prism of 
malaria elimination in the Amazon region.
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America to southern Brazil [32]. It has been demon-
strated that the species has both indoor and outdoor 
feeding and resting behaviour as well [27, 34, 35]. Fur-
thermore, An. aquasalis has been described as zoophilic 
species in Amazon region [30, 36]. Such features allow to 
classify the species as of great importance for the Latin 
America.
Even though much evidence has been generated 
regarding ivermectin effects on malaria transmission, 
some questions remain unanswered regarding its effects 
on the vector’s biology [21, 37]. Here the ivermectin 
effects on the survivorship and reproductive fitness of the 
American malaria vector An. aquasalis were assessed. 
The differences of ivermectin effect on mosquito survi-
vorship using membrane feeding assay (MFA) and direct 




Anopheles aquasalis specimens were obtained from 
a well-established colony at the Entomology Depart-
ment Insectary of the Fundação de Medicina Tropi-
cal Dr Heitor Vieira Dourado (FMT-HVD). Mosquitoes 
were raised at 26–27  °C, 70–80 % relative humidity and 
12/12 light/dark photoperiod. Larvae were fed on com-
mercial fish food (Tetramin Gold®) and adults were pro-
vided ad libitum with 10 % sucrose solution. Three to five 
days post emergence female mosquitos were used in all 
experiments.
Experimental drugs
Ivermectin tablets (Abbot Laboratórios do Brasil©) were 
supplied by FMT-HVD and the dosage was fitted accord-
ing to volunteer weight in order to have a final dosage 
of 200  µg/kg body weight, in agreement with dosages 
used during onchocerciasis MDA. Tablets of 6 mg were 
given according to weight band (51–65  kg  =  2 tablets; 
66–79 kg = 2 ½ tablets; and >80 kg = 3 tablets) follow-
ing the dosage recommendations. Powdered ivermectin 
compound was obtained from Sigma-Aldrich (St Louis, 
MO, USA) for the estimation of LC50 and reproductive 
fitness assays.
Volunteer enrolment
Subjects of both genders with medical recommenda-
tions on the use of ivermectin, according to the National 
Health Surveillance Agency (ANVISA), were enrolled 
for two assays: mosquito survivorship and blood-feeding 
type comparison, each with three male and three female 
volunteers.
For LC50 estimates and reproductive fitness experi-
ments, a single volunteer was enrolled for each objective. 
Volunteers under any treatment for diseases other than 
those mentioned, pregnant, under 18 years old, or plan-
ning to travel were not enrolled.
In vitro LC50 estimates
Powdered ivermectin compound was dissolved in 
dimethylsulfoxide to 10 mg/ml and aliquots were frozen 
at −20  °C. Before each experiment, ivermectin aliquots 
were diluted in phosphate buffered saline (PBS) and 10 µl 
of different concentrations of drug were added to 990 µl 
of blood to achieve the final concentration for blood-fed 
mosquitoes as described in detail elsewhere [20]. Blood 
samples from a single untreated volunteer were used as 
control in all experiments.
Blood meal was kept at 36  °C throughout the MFA, 
which lasted 30  min. Approximately 70 mosquitoes per 
treatment group were offered blood meal in order to have 
at least 50 engorged specimens. Fully engorged mosqui-
toes were gently transferred to 500-ml cardboard con-
tainers and kept under the same conditions as described 
above for the colonized mosquitoes. Every 24 h dead 
mosquitoes were removed and counted until the fifth day. 
Five experimental replicates of each ivermectin concen-
tration were performed in order to estimate the lethal 
concentrations in 5 days.
Effects of ivermectin drug treatment on mosquito 
survivorship
Three male and three non-pregnant female volunteers 
were enrolled in pairs for this experiment. Five ml of 
blood samples were collected at specific time points: (i) 
before drug ingestion (BDI); (ii) 4 h post-ingestion (HPI 
4); (iii) 2 days post-ingestion (DPI 2); (iv) 4 days post-
ingestion (DPI 4); (v) 7 days post-ingestion (DPI 7); and, 
(vi) 14  days post-ingestion (DPI 14). The BDI samples 
served as baseline control. Blood samples were main-
tained at 36  °C for MFA. Approximately 70 mosquitoes 
were blood fed during 30 min in order to have at least 50 
fully engorged specimens. Engorged females were gently 
transferred to a 500-ml cardboard container and kept at 
same conditions described for LC50 calculations. Dead 
mosquitoes were removed daily for 10 days and data were 
recorded. Mosquitoes fed in blood collected BDI were 
used as controls. No parallel controls were used.
Effects on reproductive fitness
Approximately 100 An. aquasalis specimens were sub-
mitted to three replicates for MFA with blood meals con-
taining a sub-lethal concentration of ivermectin (LC5). 
Ten fully engorged female mosquitoes were gently trans-
ferred to a cage containing a water bowl surrounded 
with a moist filter paper for oviposition. They were 
provided ad  libitum with 10  % sucrose solution. After 
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3 days, gravid females were dissected in order to iden-
tify retained eggs. The number of eggs laid per female 
(fecundity), number of eggs producing larvae (egg hatch 
rate) and number of pupae that developed from larvae, 
were counted on the third, fifth and seventh days post-
blood meal. Eggs, larvae and pupae were transferred to 
new containers after each counting in order to wait for 
the next instar.
Comparison of mosquito survivorship from MFA and DFA
Four experimental replicates were performed with three 
male and three female volunteers divided in two experi-
mental groups with 60–70 mosquitoes for the DFA and 
MFA. Four hours post drug ingestion, a 5-ml blood sam-
ple was collected from the volunteer for MFA and imme-
diately offered to mosquitoes. Simultaneously, a DFA 
was performed in the same volunteer for 30 min. Then, 
fully engorged females were gently transferred to 0.5-l 
containers for mortality observation as described above. 
Ten freshly engorged mosquitoes from each experimen-
tal group were quickly cold anesthetized at −20  °C and 
weighed. In order to exclude the blood meal volume 
ingested as a confounder, their weights were compared. 
Blood-fed mosquitoes were monitored daily and had 
mortality data annotated as mentioned above until the 
last specimen died.
Data analysis
A non-linear mixed model with probit analysis was 
applied to estimate in  vitro LC50, LC25 and LC5 values. 
Lethal concentration experiments with mortality back-
ground greater than 20  % were discarded and control 
mortality background lower than 20 % was corrected by 
the Abbot formula [39].
Kaplan–Meier survival analysis followed by Mantel-
Cox Log-rank test was used to evaluate both the drug 
effects on the survivorship of mosquitoes and differences 
between MFA and DFA. Additionally, proportional haz-
ard ratio was estimated by shared frailty Cox regression 
models using Breslow method in view of controlling for 
volunteer gender and multiple observations from the 
same volunteer on the survival analysis.
Differences between control and LC5 samples regard-
ing ivermectin effects on number of eggs laid per female 
(fecundity), number of eggs that produced larvae (egg 
hatch rate) and number of pupae that developed from 
larvae were estimated by a non-parametric equality-of-
medians test once the sample was not assumed to be nor-
mal distributed by the Shapiro–Wilk test.
All data was double entered in spreadsheets and Stata 
software v13 (StataCorp. 2013. Stata Statistical Software: 




Lethal concentrations were estimated according to 
data described in Table  1. LC50 fed to An. aquasalis 
was estimated as LC50  =  47.03  ng/ml [95  % CI 44.68–
49.40], LC25  =  31.92  ng/ml [95  % CI 28.60–34.57] and 
LC5 =  18.28 ng/ml [95 % CI 14.51–21.45] (n =  1415–5 
experimental replicates) (Table 1).
Effects on the mosquito survivorship
Anopheles aquasalis had significantly reduced sur-
vivorship when blood fed on volunteer blood con-
taining ivermectin HPI 4 (X2 [N  =  880]  =  328.16, 
p  <  0.001), DPI 2 (X2 [N  =  983]  =  156.75, p  <  0.001), 
DPI 7 (X2 [N = 935] = 31.17, p < 0.001) and DPI 14 (X2 
[N = 898] = 38.63, p < 0.001) compared to the blood fed 
on the untreated control. While it took approximately 
6 days to have 50  % of the mosquitoes dead in DPI 14, 
this time decreases to 4 and 3 days in DPI 2 and HPI 4, 
respectively (Fig. 1). Regression model revealed a dose–
response effect on hazard ratios (HR) for time post-inges-
tion (TPI). The HR increases while the TPI decreases. 
Proportion of dead mosquitoes was threefold increased 
for mosquitoes submitted to ivermectin blood meals HPI 
4, and 44  % higher in mosquitoes offered to ivermectin 
blood meals DPI 14 (Table 2).
Effects on reproductive fitness
Reproductive fitness was affected when mosqui-
toes were submitted to a 5  % lethal concentration 
(LC5) (18.28  ng/ml [95  % CI 14.51–21.45]). A total of 
199 blood-fed mosquitoes were allowed to egg lay-
ing substrate. In the control group, average number of 
oviposited eggs per female (34.70 [SD = 12.09]) was sig-
nificantly higher than in LC5 group (22.44 [SD = 3.38]) 
(Fig. 2a) (X2 [N = 199] = 10.52, p < 0.001). The average 
number of hatched eggs that produced larvae (egg hatch 
rate) was also significantly higher in control (81.91 
Table 1 Lethal concentrations of ivermectin for Anopheles 
aquasalis
LC lethal concentration
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[SD  =  5.92]) than in LC5 group (74.76 [SD  =  5.48]) 
(Fig. 2b) (X2 [N =  124] =  64.24, p < 0.001). Regarding 
the number of pupae that developed from larvae, no 
differences were observed between the control (34.19 
[SD  =  10.42) and LC5 group (33.33 [SD  =  11.97]) 
(Fig. 2c) (X2 [N = 124] = 0.96, p > 0.05).
Comparison between MFA and DFA
A total of 2639 fully engorged females were obtained 
from the blood-feeding assays, being 777 (29.44 %) sub-
jected to MFA and 1862 (70.56 %) from the DFA. There 
were no significant differences between blood-fed mos-
quito weight from DFA (0.040 mg [SD = 0.02]) or MFA 
(0.059  mg [SD  =  0.02]) experimental groups (t  =  1.52 
[p  >  0.05]). Survivorship of An. aquasalis blood fed in 
DFA was significantly reduced compared to MFA (Fig. 3) 
(X2 [N = 2.623] = 147.48, p < 0.001). Mosquitoes blood 
fed by DFA died faster than MFA. At the third day after 
blood meals, the survival proportion of An. aquasalis was 
less than 10 % at day 3 for DFA while it was 30 % for MFA 
(Fig. 3). Mortality percentage 2 days after feeding assays 
was significantly higher both in DFA compared to MFA 
(X2 [N  =  2.623]  =  0.2, p  <  0.05) and female compared 
Fig. 1 Effects of ivermectin on the survivorship of Anopheles aquasalis. a Mosquitoes fed on a volunteer blood meal with ivermectin 4 h post inges-
tion (HPI 4); b Mosquitoes fed on volunteers’ blood meal with ivermectin 2 days post ingestion (DPI 2); c Mosquitoes fed on volunteers’ blood meal 
with ivermectin 7 days post ingestion (DPI 7); d Mosquitoes fed on volunteers’ blood meal with ivermectin 14 days post ingestion (DPI 14)
Table 2 Shared frailty Cox model of  time post-ingestion 
effects on Anopheles aquasalis survivorship
Hazard ratios for time post-ingestion
HPI hours post ingestion, DPI days post ingestion, LR likelihood-ratio
HR [95 % CI] p value
Time post ingestion
 Control 1 –
 HPI 4 3.184 [2.775–3.653] 0.0001
 DPI 2 1.972 [1.734–2.244] 0.0001
 DPI 5 1.727 [1.510–1.976] 0.0001
 DPI 7 1.380 [1.213–1.572] 0.0001
 DPI 14 1.437 [1.259–1.640] 0.0001
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to male volunteers (X2 [N =  2.623] =  412.7, p  <  0.001) 
(Fig. 4).
Shared frailty Cox model showed that DFA blood-
fed mosquitoes compared to MFA had a 73  % increase 
of mortality rate adjusting for volunteers’ gender 
(HR = 1.726 [1.573–1.895] p = 0.0001). Once more, vol-
unteers’ gender was assessed as an effect modifier and the 
regression model revealed an increase of risk for women 
volunteers (1.409 [1.295–1.532] p < 0.001) (Table 3).
Discussion
Malaria elimination is an ambitious objective that has 
now been seriously considered and embraced both by 
the public health community and scientists worldwide. In 
this scenario, ivermectin has appeared as a potential com-
plementary tool for elimination as it effectively targets 
outdoor transmission, has a novel mechanism of action 
that might bypass occurrence of resistance and could uti-
lize implementation mechanisms that are already func-
tional because of efforts to control other diseases, such 
as onchocerciasis and lymphatic filariasis [21]. Moreover, 
the drug has been reported to reduce vectorial capacity 
for Plasmodium transmission, both by reducing mos-
quito survival and possibly inhibiting Plasmodium fal-
ciparum sporogony [38, 39]. Even so, and despite recent 
discoveries, little is known about the effects of the drug 
on the biology of different vectors, especially from Latin 
America [27].
Fig. 2 Effects of ivermectin on the reproductive fitness of Anopheles aquasalis. a Effects on number of eggs per female (fecundity); b Effects on 
eggs that produced larvae (eggs hatch rate); c Effects on number of pupae that developed from larvae
Fig. 3 Kaplan–Meier survival function curves. Comparison of dif-
ferent blood meal types. Survival proportion significantly increased 
in DFA compared with MFA (X2 [N = 2.623] = 0.2, p < 0.05). MFA 
membrane feeding assay, DFA direct feeding assay
Fig. 4 Mortality proportion of mosquitoes fed with blood contain-
ing ivermectin at the second day after blood meals. Comparison of 
MFA and DFA methods (p < 0.001) and between male and female 
volunteers (p < 0.001). MFA membrane feeding assay, DFA direct 
feeding assay
Table 3 Shared frailty Cox model of  feeding assay effect 
on Anopheles aquasalis survivorship
MFA membrane feeding assay, DFA direct feeding assay
HR [95 % CI] p value
Feeding type
 MFA 1 –
 DFA 1.726 [1.573–1.895] 0.0001
Gender
 Male 1 –
 Female 1.314 [1.199–1.442] 0.0001
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In this study, the effects of ivermectin on An. aqua-
salis survivorship and reproduction are showed for 
the first time. Ivermectin was shown to increase 
mortality and reduce reproductive capacity of An. 
aquasalis. The An. aquasalis ivermectin lethal con-
centrations (LC50  =  47.03  ng/ml, LC25  =  31.92  ng/ml, 
LC5 = 18.28 ng/ml) are higher than calculated previously 
for Anopheles gambiae [17, 20] but still within human rel-
evant range following oral treatment with 150–200 μg/kg 
[39, 40]. It must be noted that the methods used here and 
firstly used by Kobilinsky et al. [17] for LC estimates dif-
fer from others since an in vitro mixing of drug and blood 
was used instead of blood from treated subjects and this 
method could be influencing the higher LC values found 
here. Because single doses of 200  μg/kg can only keep 
blood concentrations compatible with this lethal con-
centrations for a short period, using higher or repeated 
doses or slow release formulations of ivermectin should 
be considered as a feasible strategy. These data allow to 
infer that ivermectin treatment of humans should impart 
a lethal effect on An. aquasalis.
In vivo data revealed that mosquitoes fed on volunteer 
blood containing ivermectin (200  µg/kg) at 4 h, 2, 4, 7, 
and 14  days post drug ingestion significantly reduced 
survivorship compared to those fed on untreated control 
individual blood. These findings are similar to Foley et al. 
[15] which showed survivorship reduction for Anopheles 
farauti until 14  days post ivermectin ingestion (250  μg/
kg) by DFA. Ivermectin seems to have great affinity for 
adipose tissue. Strongly lipid binding may cause its slow 
release, thereby increasing its persistence in the body, as 
suggested previously [41, 42, 43]. This phenomenon may 
explain why mosquito lethal effects were observed as 
late as 14  days post drug ingestion. Increasing the dose 
of ivermectin would likely impart a greater effect against 
An. aquasalis for a longer period of time.
Ivermectin sub-lethal effects on the reproductive fit-
ness of Anopheles mosquitoes were first reported by 
Gardner et al. [44] in Anopheles quadrimaculatus speci-
mens fed canine blood containing ivermectin. Two stud-
ies indicate that ivermectin treatment of cattle reduces 
mosquito fecundity for Anopheles coluzzii [45] and An. 
gambiae s.s. [46]. A complete inhibition of An. gambiae 
fecundity when mosquitoes fed on human blood 24 h 
post treatment with a 150–200 µg/kg dosage was shown 
by Derua et  al. [47]. The findings support and extend 
studies since was demonstrated that ivermectin effects 
on eggs/female proportion, eggs hatchability and even 
on pupae/larvae proportion under a low concentra-
tion dosage. Additionally it should be appreciated that 
human pharmacokinetic may differ from those in ani-
mals, as in the first three studies, domesticated animals 
were injected with doses varying from 6 to 600  µg/kg. 
These findings reinforce the hypothesis that even sub-
lethal doses of ivermectin could play an important role 
on altering the vectorial capacity.
Studies conducted on ivermectin effects over mosqui-
toes are usually carried out through MFA [19, 42, 44]. 
As described previously, since ivermectin is lipophilic, it 
usually binds to fatty tissue where it may lead to higher 
concentrations in different compartments. This feature, 
in turn, led to believe that mosquitoes fed by DFA on 
sub-dermal capillaries may ingest higher ivermectin con-
centrations than mosquitoes fed by MFA with venous 
blood, imparting a greater mosquito lethal effect, as sug-
gested by Chaccour et al. [27]. Here was also showed sig-
nificant differences between MFA and DFA HRs (1.54 
[1.406–1.684] p  <  0.001) adjusting for volunteer gender. 
Although the limited number of volunteers (3 males and 
3 females) may be a limitation for the study, these are 
exciting findings since previous results obtained from 
MFA studies may be underestimates of the real effects 
that occur during direct feeding after ivermectin MDA 
during a malaria elimination campaign. Regression 
model also revealed an increased risk for mosquitoes 
feeding on women volunteers independent of the blood 
feeding assay in accordance with a recent study reporting 
a greater availability of ivermectin in female human and 
in higher body mass indices volunteers [42]. Since only 
one single time point (4 h post-ingestion) was evaluated, 
additional studies must be carried out in order to assess 
these differences in later time-points where the effect of 
ivermectin decreases.
Conclusions
Ivermectin has proven to be effective against a range of 
malaria vectors worldwide. The drug affects many aspects 
of both vector biology and its vectorial capacity as well. 
Considering the diversity of environment in the Amazon 
region and consequently of entomological and epide-
miological scenarios, malaria elimination campaigns in 
Amazon must resort to concomitant multiple strategies. 
Here a gap of knowledge regarding ivermectin effects on 
an important Amazon vector species, An. aquasalis was 
filled. It was demonstrated that ivermectin impacts mos-
quito survivorship for up to 14  days post-ingestion and 
has a deleterious effect on the vector reproductive fitness. 
Significant difference between MFA and DFA was found 
and no difference concerning blood meal volume com-
paring MFA and DFA was shown. Considering the find-
ings, malaria elimination strategies in the Amazon could 
benefit from having ivermectin as an additional tool, 
which would readily complement the effect of the use of 
drugs for population treatment, or other vector control 
mechanism. Since outdoor transmission in Amazon has a 
relevant contribution to the overall malaria transmission 
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and the ivermectin way of action influences this, the 
drug would likely have an impact on the incidence of dis-
ease in the region. Furthermore, since An. aquasalis is 
incriminated both as zoophilic and anthropophilic, has 
a widespread distribution and is implicated in malaria 
transmission as well, it seems to be feasible the deploy-
ment of strategies focused on cattle and/or human treat-
ment. Future investigation concerning ivermectin effects 
on other important Amazonian species, such as Anoph-
eles darlingi and Anopheles albitarsis, should be assessed 
prior to widespread adoption of ivermectin as a malaria 
elimination tool in the Amazon.
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